Blog
Overcoming the obstacles of neoantigen identification
Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.READ MORE
Resistance to immunotherapy: The elusive routes of immune escape
Achieving a durable clinical response is the ultimate goal in immuno-oncology clinical trials. With immunotherapies showing long-lasting, unprecedented responses in cancer indications such as melanoma and Non-Small Cell Lung Cancer (NSCLC), these immune-boosting drugs seem to be displaying genuine advancesREAD MORE
Is timing everything?
Unlike targeted therapies, there tends to be general agreement that it is unlikely that a single predictive biomarker in tumor biopsies will be found for determining response to immunotherapies.READ MORE
The importance of cellular neoantigens for immuno-oncology in virus-associated cancers
Approximately 12% of human cancers are associated with viral infection, including a majority of cervical cancers, Merkel cell carcinomas, and oropharyngeal cancer cases, along with significant proportions of other head and neck cancers and hepatocellular carcinomas.READ MORE
Combination therapies on the rise: Reflections from Immunotherapy World 2017
Back in October of 2016, Christelle Johnson provided an excellent blog, The state of Combination Therapies in Immuno-Oncology. This emphasis on combination strategies continues to resonate throughout the scientific community and has been highlighted at several recent conferences.READ MORE